<b><i>Purpose:</i></b> This paper aims to describe the current situation of choroidal neovascularization (CNV) treatment. <b><i>Procedures:</i></b> MEDLINE (2001-2013) was searched for original research studies (phase I, II, III), abstracts and review articles concerning CNV therapy, and other related articles. Selected information from related websites was also included. <b><i>Results:</i></b> The management of CNV was developed through laser photocoagulation and photodynamic therapy, and has now evolved into anti-vascular endothelial growth factor (VEGF) use. Patients have achieved better visual acuity and toleration with the development of this therapy strategy. Combination therapy appears to offer a reduced retreatment frequency and long-term maintenance of the benefit with appropriate combination. Other treatment explorations with anti-inflammation and anti-VEGF are also ongoing. <b><i>Conclusions:</i></b> Anti-VEGF monotherapy has become the first treatment for CNV patients. The investigation of other therapy strategies may prolong the interval of treatment and provide alternatives to CNV treatment.